The clinical significance of urine diacetylspermine level as a tumor marker for lung cancer

Masato Kato, Hideya Ohnishi, Hiroyuki Suzuki, Nobuko Tsuruta, Kazuyuki Higuchi, Mitsuo Katano

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective. The aim of the present study was to define the usefulness of a urine tumor marker, di-acetylspermine (DiAcSpm) in patients with lung cancer. Materials and Methods. Of the patients who were treated for lung cancer from August 2003 to September 2010 in our hospital, 308 (non-small cell lung cancer-296, small cell lung cancer-12) were enrolled in this study. We compared the urine tumor marker, DiAcSpm with serum tumor markers (CEA, CYFRA21-1 and Pro-GRP). Besults. The sensitivity of urine DiAcSpm (46.4%) was significantly higher than that of serum CEA (32.7%) and serum CYFRA21-1 (23.7%). The specificity of urine DiAcSpm (90.6%) was similar to that of serum CEA (87.5%) and serum CYFRA21-1 (93.8%). We then compared the sensitivities of DiAcSpm and other markers among subjects according to tumor stage. The sensitivity of DiAcSpm was higher than that of CYFRA21-1 in Stage IA and IB patients, and CEA in Stage IIIB and IV patients, while the proportion of positive results for each marker increased with progression of the cancer. In particular, DiAcSpm was markedly elevated in 25.5% and 42.6% of Stage IA and IB patients, respectively, whereas only 5.4% and 18.5% of these patients were CYFRA21-1-positive, respectively. Pathologically, the sensitivity of urine DiAcSpm was markedly higher in patients with adenocarcinoma (39.5%) compared to CYFRA21-1 (17.3%), and in squamous cell carcinoma (62.0%) compared with CEA (33.3%) and SCC antigen (49.0%). Conclusion. These results suggest that urine DiAcSpm is useful as a tumor marker for lung cancer, because it is more sensitive than the serum markers currently in clinical use.

Original languageEnglish
Pages (from-to)787-792
Number of pages6
JournalJapanese Journal of Lung Cancer
Volume51
Issue number7
DOIs
Publication statusPublished - Dec 1 2011

Fingerprint

Tumor Biomarkers
Lung Neoplasms
Urine
Serum
Biomarkers
Small Cell Lung Carcinoma
N',N''-diacetylspermine
Non-Small Cell Lung Carcinoma
Squamous Cell Carcinoma
Neoplasms
Adenocarcinoma

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

The clinical significance of urine diacetylspermine level as a tumor marker for lung cancer. / Kato, Masato; Ohnishi, Hideya; Suzuki, Hiroyuki; Tsuruta, Nobuko; Higuchi, Kazuyuki; Katano, Mitsuo.

In: Japanese Journal of Lung Cancer, Vol. 51, No. 7, 01.12.2011, p. 787-792.

Research output: Contribution to journalArticle

Kato, Masato ; Ohnishi, Hideya ; Suzuki, Hiroyuki ; Tsuruta, Nobuko ; Higuchi, Kazuyuki ; Katano, Mitsuo. / The clinical significance of urine diacetylspermine level as a tumor marker for lung cancer. In: Japanese Journal of Lung Cancer. 2011 ; Vol. 51, No. 7. pp. 787-792.
@article{2bbb0021c6844d3faed7d45517196ffc,
title = "The clinical significance of urine diacetylspermine level as a tumor marker for lung cancer",
abstract = "Objective. The aim of the present study was to define the usefulness of a urine tumor marker, di-acetylspermine (DiAcSpm) in patients with lung cancer. Materials and Methods. Of the patients who were treated for lung cancer from August 2003 to September 2010 in our hospital, 308 (non-small cell lung cancer-296, small cell lung cancer-12) were enrolled in this study. We compared the urine tumor marker, DiAcSpm with serum tumor markers (CEA, CYFRA21-1 and Pro-GRP). Besults. The sensitivity of urine DiAcSpm (46.4{\%}) was significantly higher than that of serum CEA (32.7{\%}) and serum CYFRA21-1 (23.7{\%}). The specificity of urine DiAcSpm (90.6{\%}) was similar to that of serum CEA (87.5{\%}) and serum CYFRA21-1 (93.8{\%}). We then compared the sensitivities of DiAcSpm and other markers among subjects according to tumor stage. The sensitivity of DiAcSpm was higher than that of CYFRA21-1 in Stage IA and IB patients, and CEA in Stage IIIB and IV patients, while the proportion of positive results for each marker increased with progression of the cancer. In particular, DiAcSpm was markedly elevated in 25.5{\%} and 42.6{\%} of Stage IA and IB patients, respectively, whereas only 5.4{\%} and 18.5{\%} of these patients were CYFRA21-1-positive, respectively. Pathologically, the sensitivity of urine DiAcSpm was markedly higher in patients with adenocarcinoma (39.5{\%}) compared to CYFRA21-1 (17.3{\%}), and in squamous cell carcinoma (62.0{\%}) compared with CEA (33.3{\%}) and SCC antigen (49.0{\%}). Conclusion. These results suggest that urine DiAcSpm is useful as a tumor marker for lung cancer, because it is more sensitive than the serum markers currently in clinical use.",
author = "Masato Kato and Hideya Ohnishi and Hiroyuki Suzuki and Nobuko Tsuruta and Kazuyuki Higuchi and Mitsuo Katano",
year = "2011",
month = "12",
day = "1",
doi = "10.2482/haigan.51.787",
language = "English",
volume = "51",
pages = "787--792",
journal = "Japanese Journal of Lung Cancer",
issn = "0386-9628",
publisher = "Japan Lung Cancer Society",
number = "7",

}

TY - JOUR

T1 - The clinical significance of urine diacetylspermine level as a tumor marker for lung cancer

AU - Kato, Masato

AU - Ohnishi, Hideya

AU - Suzuki, Hiroyuki

AU - Tsuruta, Nobuko

AU - Higuchi, Kazuyuki

AU - Katano, Mitsuo

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Objective. The aim of the present study was to define the usefulness of a urine tumor marker, di-acetylspermine (DiAcSpm) in patients with lung cancer. Materials and Methods. Of the patients who were treated for lung cancer from August 2003 to September 2010 in our hospital, 308 (non-small cell lung cancer-296, small cell lung cancer-12) were enrolled in this study. We compared the urine tumor marker, DiAcSpm with serum tumor markers (CEA, CYFRA21-1 and Pro-GRP). Besults. The sensitivity of urine DiAcSpm (46.4%) was significantly higher than that of serum CEA (32.7%) and serum CYFRA21-1 (23.7%). The specificity of urine DiAcSpm (90.6%) was similar to that of serum CEA (87.5%) and serum CYFRA21-1 (93.8%). We then compared the sensitivities of DiAcSpm and other markers among subjects according to tumor stage. The sensitivity of DiAcSpm was higher than that of CYFRA21-1 in Stage IA and IB patients, and CEA in Stage IIIB and IV patients, while the proportion of positive results for each marker increased with progression of the cancer. In particular, DiAcSpm was markedly elevated in 25.5% and 42.6% of Stage IA and IB patients, respectively, whereas only 5.4% and 18.5% of these patients were CYFRA21-1-positive, respectively. Pathologically, the sensitivity of urine DiAcSpm was markedly higher in patients with adenocarcinoma (39.5%) compared to CYFRA21-1 (17.3%), and in squamous cell carcinoma (62.0%) compared with CEA (33.3%) and SCC antigen (49.0%). Conclusion. These results suggest that urine DiAcSpm is useful as a tumor marker for lung cancer, because it is more sensitive than the serum markers currently in clinical use.

AB - Objective. The aim of the present study was to define the usefulness of a urine tumor marker, di-acetylspermine (DiAcSpm) in patients with lung cancer. Materials and Methods. Of the patients who were treated for lung cancer from August 2003 to September 2010 in our hospital, 308 (non-small cell lung cancer-296, small cell lung cancer-12) were enrolled in this study. We compared the urine tumor marker, DiAcSpm with serum tumor markers (CEA, CYFRA21-1 and Pro-GRP). Besults. The sensitivity of urine DiAcSpm (46.4%) was significantly higher than that of serum CEA (32.7%) and serum CYFRA21-1 (23.7%). The specificity of urine DiAcSpm (90.6%) was similar to that of serum CEA (87.5%) and serum CYFRA21-1 (93.8%). We then compared the sensitivities of DiAcSpm and other markers among subjects according to tumor stage. The sensitivity of DiAcSpm was higher than that of CYFRA21-1 in Stage IA and IB patients, and CEA in Stage IIIB and IV patients, while the proportion of positive results for each marker increased with progression of the cancer. In particular, DiAcSpm was markedly elevated in 25.5% and 42.6% of Stage IA and IB patients, respectively, whereas only 5.4% and 18.5% of these patients were CYFRA21-1-positive, respectively. Pathologically, the sensitivity of urine DiAcSpm was markedly higher in patients with adenocarcinoma (39.5%) compared to CYFRA21-1 (17.3%), and in squamous cell carcinoma (62.0%) compared with CEA (33.3%) and SCC antigen (49.0%). Conclusion. These results suggest that urine DiAcSpm is useful as a tumor marker for lung cancer, because it is more sensitive than the serum markers currently in clinical use.

UR - http://www.scopus.com/inward/record.url?scp=84863411610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863411610&partnerID=8YFLogxK

U2 - 10.2482/haigan.51.787

DO - 10.2482/haigan.51.787

M3 - Article

VL - 51

SP - 787

EP - 792

JO - Japanese Journal of Lung Cancer

JF - Japanese Journal of Lung Cancer

SN - 0386-9628

IS - 7

ER -